|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.38 USD | -0.67% |
|
+3.65% | +62.20% |
| 05-09 | Larimar Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-09 | Zafgen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Zafgen, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 14.65 million compared to USD 6.53 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to USD 0.15 a year ago.
Diluted loss per share from continuing operations was USD 0.27 compared to USD 0.15 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +62.20% | 471M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -2.42% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
LARIMAR THERAPEUTICS, INC. 
